Treatment of brain metastases of HER2-positive breast cancer

被引：0

作者：

Heudel, P. ^{[1
]}

Tredan, O. ^{[1
]}

Cassier, P. ^{[1
]}

Ray-Coquard, I. ^{[1
]}

Guastalla, J. -P. ^{[1
]}

Bachelot, T. ^{[1
]}

机构：

[1] Ctr Leon Berard, Dept Med Oncol, F-69008 Lyon, France

来源：

ONCOLOGIE | 2012年 / 14卷 / 01期

关键词：

Brain metastases; Breast cancer; Anti-HER2; treatment; PHASE-II; MENINGEAL CARCINOMATOSIS; CNS METASTASES; RADIOTHERAPY; CAPECITABINE; TEMOZOLOMIDE; LAPATINIB; TRIAL; CHEMOTHERAPY; CISPLATIN;

D O I：

10.1007/s10269-011-2107-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is the second leading cause of brain metastases. In patients with HER2-positive breast cancer, the incidence of brain metastases is 40%. Although the arrival of anti-HER2 therapies has meant better control of other metastatic diseases, progress still needs to be made with regard to therapies for treating brain metastases. Currently, research is concentrating on chemoradiotherapy combinations, anti-HER2 and chemotherapy combinations, more specifically, combining lapatinib and capecitabine, or even intrathecal administration of herceptin. To cite this journal: Oncologie 14 (2012).

引用

收藏

页码：41 / 44

页数：4

相关论文

共 22 条

[1] Phase 2 Trial of Temozolomide Using Protracted Low-dose and Whole-brain Radiotherapy for Nonsmall Cell Lung Cancer and Breast Cancer Patients With Brain Metastases [J].

Addeo, Raffaele ;

De Rosa, Carmine ;

Faiola, Vincenzo ;

Leo, Luigi ;

Cennamo, Gregorio ;

Montella, Liliana ;

Guarrasi, Rosario ;

Vincenzi, Bruno ;

Caraglia, Michele ;

Del Prete, Salvatore .

CANCER, 2008, 113 (09) :2524-2531

[2] Phase II Randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases [J].

Antonadou, D ;

Paraskevaidis, M ;

Sarris, G ;

Coliarakis, N ;

Economou, I ;

Karageorgis, P ;

Throuvalas, N .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3644-3650

[3]

Bachelot T, 2011, J CLIN ONCOL, V29, P509

[4] Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma [J].

Bendell, JC ;

Domchek, SM ;

Burstein, HJ ;

Harris, L ;

Younger, J ;

Kuter, I ;

Bunnell, C ;

Rue, M ;

Gelman, R ;

Winer, E .

CANCER, 2003, 97 (12) :2972-2977

[5] A Phase 2 Trial of Whole-brain Radiotherapy Combined With Intravenous Chemotherapy in Patients With Brain Metastases From Breast Cancer [J].

Cassier, Philippe A. ;

Ray-Coquard, Isabelle ;

Sunyach, Marie-Pierre ;

Lancry, Laurence ;

Guastalla, Jean-Paul ;

Ferlay, Celine ;

Gomez, Frederic ;

Cure, Herve ;

Lortholary, Alain ;

Claude, Line ;

Blay, Jean-Yves ;

Bachelot, Thomas .

CANCER, 2008, 113 (09) :2532-2538

[6] Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients [J].

Chargari, Cyrus ;

Kirova, Youlia M. ;

Dieras, Veronique ;

Pena, Pablo Castro ;

Campana, Francois ;

Cottu, Paul H. ;

Pierga, JeanYves ;

Fourquet, Alain .

JOURNAL OF NEURO-ONCOLOGY, 2009, 93 (03) :379-384

[7] Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study [J].

Christodoulou, C ;

Bafaloukos, D ;

Linardou, H ;

Aravantinos, G ;

Bamias, A ;

Carina, M ;

Klouvas, G ;

Skarlos, D .

JOURNAL OF NEURO-ONCOLOGY, 2005, 71 (01) :61-65

[8]

Franciosi V, 1999, CANCER, V85, P1599, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.3.CO

[9]

2-R

[10] Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment? [J].

Gutierrez, Maya ;

Lyazidi, Souad ;

Brasseur, Louis ;

Cvitkovic, Frederique ;

Le Scodan, Romuald .

BULLETIN DU CANCER, 2011, 98 (04) :417-424